BioCentury | Feb 3, 2021
Finance

Abingworth leans into company creation with largest-ever fund at $465M

...& Co. (NYSE:LLY), PPD Inc. (NASDAQ:PPD) and Catalent Inc....
BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

...save the company $40 million annually. The biotech entered a supply agreement with the buyer, Catalent Inc....
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

...Juniper Pharmaceuticals Inc., which was acquired by Catalent Inc....
BioCentury | Dec 18, 2020
Product Development

Realities of limited manufacturing capacity for COVID-19 vaccines hit Horizon’s Tepezza launch

...which means delays for patients hoping to start treatment with the drug. Horizon’s contract manufacturer is Catalent Inc....
...Catalent to provide large scale fill-finish manufacturing for COVID vaccine mRNA-1273. A Horizon spokesperson said Catalent...
...manufacturing.TARGETSIGF1R (CD221) – Insulin-like growth factor-1 (IGF-1) receptor Stephen Hansen Tepezza, teprotumumab (hzn-001, rv001, r1507, rg1507) Horizon Therapeutics plc Catalent Inc. cov19count covid-19 Operation...
BioCentury | Jun 26, 2020
Product Development

Pfizer, BioNTech on track to make hundreds of millions of COVID-19 vaccine doses this year

...Also agreeing to vaccine manufacturing deals this week were Moderna Inc. (NASDAQ:MRNA), which partnered with Catalent Inc....
BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

...This week, six of the nine companies priced offerings at or above $100 million, with Catalent Inc....
...therapy manufacturer raised $550 million Thursday through the sale of an undisclosed number of shares; Catalent...
...Inc. (NASDAQ:IMUX), which raised $25 million Wednesday. Elizabeth S. Eaton, Staff Writer Moderna Inc. Guardant Health Inc. Allogene Therapeutics Inc. Catalent Inc. ChemoCentryx...
BioCentury | Jun 6, 2020
Product Development

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

...28, the AAVCOVID team announced manufacturing partnerships with AveXis as well as CDMOs Aldevron LLC, Catalent Inc....
...produced by Aldevron go to AveXis for insertion into the AAV vector, and finally to Catalent...
...into AAV vectors manufactured by Viralgen; QC can then be performed by either Viralgen or Catalent...
BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

...manufacturing partnerships with the AveXis unit of Novartis AG (NYSE:NVS; SIX:NOVN) and CDMOs Aldevron LLC, Catalent Inc....
...off in later phases to AveXis for manufacturing and additional testing.” The Viralgen, Aldevron and Catalent...
...per batch. North Dakota-based Aldevron is supplying DNA plasmids that serve as payloads for AAVCOVID. Catalent...
BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

...can produce a billion doses per year or more. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) and Catalent Inc....
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Jonathan Freve as CFO. He was CFO of Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH). Robin Sawka, BioCentury Staff Catalent Inc. Stanford...
Items per page:
1 - 10 of 104
BioCentury | Feb 3, 2021
Finance

Abingworth leans into company creation with largest-ever fund at $465M

...& Co. (NYSE:LLY), PPD Inc. (NASDAQ:PPD) and Catalent Inc....
BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

...save the company $40 million annually. The biotech entered a supply agreement with the buyer, Catalent Inc....
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

...Juniper Pharmaceuticals Inc., which was acquired by Catalent Inc....
BioCentury | Dec 18, 2020
Product Development

Realities of limited manufacturing capacity for COVID-19 vaccines hit Horizon’s Tepezza launch

...which means delays for patients hoping to start treatment with the drug. Horizon’s contract manufacturer is Catalent Inc....
...Catalent to provide large scale fill-finish manufacturing for COVID vaccine mRNA-1273. A Horizon spokesperson said Catalent...
...manufacturing.TARGETSIGF1R (CD221) – Insulin-like growth factor-1 (IGF-1) receptor Stephen Hansen Tepezza, teprotumumab (hzn-001, rv001, r1507, rg1507) Horizon Therapeutics plc Catalent Inc. cov19count covid-19 Operation...
BioCentury | Jun 26, 2020
Product Development

Pfizer, BioNTech on track to make hundreds of millions of COVID-19 vaccine doses this year

...Also agreeing to vaccine manufacturing deals this week were Moderna Inc. (NASDAQ:MRNA), which partnered with Catalent Inc....
BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

...This week, six of the nine companies priced offerings at or above $100 million, with Catalent Inc....
...therapy manufacturer raised $550 million Thursday through the sale of an undisclosed number of shares; Catalent...
...Inc. (NASDAQ:IMUX), which raised $25 million Wednesday. Elizabeth S. Eaton, Staff Writer Moderna Inc. Guardant Health Inc. Allogene Therapeutics Inc. Catalent Inc. ChemoCentryx...
BioCentury | Jun 6, 2020
Product Development

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

...28, the AAVCOVID team announced manufacturing partnerships with AveXis as well as CDMOs Aldevron LLC, Catalent Inc....
...produced by Aldevron go to AveXis for insertion into the AAV vector, and finally to Catalent...
...into AAV vectors manufactured by Viralgen; QC can then be performed by either Viralgen or Catalent...
BioCentury | May 28, 2020
Product Development

Mass General counts AveXis, James Wilson among partners as it readies to deploy gene therapy tools for COVID-19 vaccine

...manufacturing partnerships with the AveXis unit of Novartis AG (NYSE:NVS; SIX:NOVN) and CDMOs Aldevron LLC, Catalent Inc....
...off in later phases to AveXis for manufacturing and additional testing.” The Viralgen, Aldevron and Catalent...
...per batch. North Dakota-based Aldevron is supplying DNA plasmids that serve as payloads for AAVCOVID. Catalent...
BioCentury | May 21, 2020
Product Development

Translate Bio brings chronic disease-scale manufacturing to COVID-19 mRNA vaccine

...can produce a billion doses per year or more. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) and Catalent Inc....
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Jonathan Freve as CFO. He was CFO of Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH). Robin Sawka, BioCentury Staff Catalent Inc. Stanford...
Items per page:
1 - 10 of 104